



Press Release

for  
**immediate**  
release

## **Teva Announces Sale of UK and Ireland Actavis Assets and Operations**

**Jerusalem, Oct. 5 2016** – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it has agreed to sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd) for an agreed value of GBP 603 million, subject to final approval from the European Commission.

The divestment of certain specified Actavis Generics assets and operations in the UK and Ireland was part of an undertaking that Teva made to the European Commission in the context of the review of the acquisition of Actavis Generics by Teva earlier this year. The sale will include a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England. Teva retains a number of Actavis non-overlapping generic products plus certain specialty medicines and OTC (over-the-counter) products, which have been added to Teva's existing operations.

"The sale has been a success for Teva in that we have satisfied the EU Commission's sale requirements for these businesses, subject to their final approval, and agreed on a good price for the assets. With the assets that it will retain, Teva will create an even stronger operation in the UK and Ireland," commented Siggí Olafsson, President & CEO Global Generic Medicines Teva. "Teva is the leading provider of medicines to the UK National Health Service, and the addition of the retained Actavis assets strengthens our ability to be the partner of choice in these countries while preserving strong and healthy competition in a competitive marketplace."

The transaction is expected to close in the next three months. Greenhill & Co. are serving as financial advisors to Teva, and Pinsent Masons are serving as legal counsel to Teva in respect of this transaction.

### **About Teva**

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to \$19.7 billion. For more information, visit [www.tevapharm.com](http://www.tevapharm.com).

### **Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:**

*This release contains forward-looking statements, which are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our specialty products, especially Copaxone® (which faces competition from orally-administered alternatives and a*



# Press Release

for  
**immediate**  
release

*generic version); our ability to integrate Allergan plc's worldwide generic pharmaceuticals business ("Actavis Generics") and to realize the anticipated benefits of the acquisition (and the timing of realizing such benefits); the fact that following the consummation of the Actavis Generics acquisition, we are dependent to a much larger extent than previously on our generic pharmaceutical business; potential restrictions on our ability to engage in additional transactions or incur additional indebtedness as a result of the substantial amount of debt incurred to finance the Actavis Generics acquisition; the fact that for a period of time following the Actavis Generics acquisition, we will have significantly less cash on hand than previously, which could adversely affect our ability to grow; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from investments in our pipeline of specialty and other products; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with the U.S. Securities and Exchange Commission (the "SEC"). Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statements or other information, whether as a result of new information, future events or otherwise.*

###

-2-

---

IR Contacts:	<b>Kevin C. Mannix</b>	United States	(215) 591-8912
	<b>Ran Meir</b>	United States	(215) 591-3033
	<b>Tomer Amitai</b>	Israel	972 (3) 926-7656
PR Contacts:	<b>Iris Beck Codner</b>	Israel	972 (3) 926-7687
	<b>Denise Bradley</b>	United States	(215) 591-8974

## טבע מודיעה על מכירת נכסים ופעילויות של אקטביס בבריטניה ובאירלנד

ירושלים, 5 באוקטובר 2016 - טבע תעשיות פרמצבטיות בע"מ (NYSE ו-TASE: TEVA) הודיעה כי הסכימה למכור נכסים ופעילויות של אקטביס ג'נריקס בבריטניה ובאירלנד ל-Accord Healthcare Limited (חברה בת של Intas Pharmaceuticals Ltd) עבור סכום מוסכם של 603 מיליון פאונד, בכפוף לאישור סופי של המועצה האירופית.

מכירת נכסים מסוימים של אקטביס ג'נריקס בבריטניה ובאירלנד היתה חלק מהתחייבות אשר הגישה טבע במסגרת הליך האישור הרגולטורי כחלק מבחינת רכישת אקטביס ג'נריקס על ידי טבע, מוקדם יותר השנה. המכירה תכלול פורטפוליו של תרופות גנריות וכן מפעל ייצור בברנסטייפל, אנגליה. טבע תשמור אצלה מספר מוצרים גנריים לא חופפים של אקטביס, וכן תרופות מקור ומוצרים ללא מרשם אשר התווספו לפעילות הקיימת של טבע.

"מכירה זו הינה הצלחה עבור טבע שכן היא משיגה את דרישות המכירה שהציבה המועצה האירופית, והכל בכפוף לאישור סופי, והשיגה מחיר טוב עבור הנכסים. באמצעות הנכסים שטבע תשמר בידה, בנתה טבע פעילות חזקה אף יותר בבריטניה ובאירלנד, " אמר סיגי אולפסון, נשיא ומנכ"ל קבוצת הגנריקה הגלובלית בטבע. "טבע היא הספקית המובילה של תרופות לשירות הבריאות הלאומי בבריטניה, והוספת נכסי אקטביס אשר יישארו בידיו מחזקת את יכולתנו להיות הבחירה המועדפת במדינות אלו תוך שימור תחרות חזקה ובריאה בשוק תחרותי."

העסקה צפויה להיסגר במהלך שלושת החודשים הבאים. Greenhill & Co משמשים כיועצים הכספיים לטבע, ו-Pinsent Mason משמשים כיועצים המשפטיים לטבע בנוגע לעסקה זו.

### אודות טבע

טבע תעשיות פרמצבטיות בע"מ (NYSE & TASE: TEVA) היא חברת תרופות גלובלית המספקת פתרונות בריאות ממוקדי-מטופל באיכות גבוהה המשמשים מיליוני מטופלים מדי יום. טבע, שבסיסה בישראל, היא יצרנית התרופות הגנריות הגדולה בעולם, הממנפת את צבר מוצריה הכולל יותר מ-1,800 מולקולות לייצר מגוון רחב של מוצרים גנריים ברוב התחומים הטיפולים. בתחום התרופות הייחודיות, טבע הינה חברה מובילה בטיפולים חדשניים למחלות מערכת העצבים המרכזית, כולל כאב, והיא מחזיקה גם צבר מוצרים חזק בתחום מחלות הנשימה. טבע משלבת את כישוריה בתחום התרופות הגנריות ובתחום התרופות הייחודיות בחטיבת המחקר והפיתוח הגלובלית שלה, במטרה ליצור דרכים חדשות לענות על צרכי המטופלים וזאת על ידי שילוב יכולות בתחום פיתוח תרופות יחד עם פיתוח תכשירים, שירותים וטכנולוגיות. הכנסות טבע בשנת 2015 הסתכמו ב-\$19.7 מיליארד. למידע נוסף על החברה, בקרו באתר [www.tevapharm.com](http://www.tevapharm.com).

### Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:

-2-

IR Contacts:	Kevin C. Mannix	United States	(215) 591-8912
	Ran Meir	United States	(215) 591-3033
	Tomer Amitai	Israel	972 (3) 926-7656
PR Contacts:	Iris Beck Codner	Israel	972 (3) 926-7687
	Denise Bradley	United States	(215) 591-8974



# Press Release

for  
**immediate**  
release

This release contains forward-looking statements, which are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our specialty products, especially Copaxone® (which faces competition from orally-administered alternatives and a generic version); our ability to integrate Allergan plc's worldwide generic pharmaceuticals business ("Actavis Generics") and to realize the anticipated benefits of the acquisition (and the timing of realizing such benefits); the fact that following the consummation of the Actavis Generics acquisition, we are dependent to a much larger extent than previously on our generic pharmaceutical business; potential restrictions on our ability to engage in additional transactions or incur additional indebtedness as a result of the substantial amount of debt incurred to finance the Actavis Generics acquisition; the fact that for a period of time following the Actavis Generics acquisition, we will have significantly less cash on hand than previously, which could adversely affect our ability to grow; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from investments in our pipeline of specialty and other products; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent

-2-

---

IR Contacts:	<b>Kevin C. Mannix</b>	United States	(215) 591-8912
	<b>Ran Meir</b>	United States	(215) 591-3033
	<b>Tomer Amitai</b>	Israel	972 (3) 926-7656
PR Contacts:	<b>Iris Beck Codner</b>	Israel	972 (3) 926-7687
	<b>Denise Bradley</b>	United States	(215) 591-8974



# Press Release

for  
**immediate**  
release

laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with the U.S. Securities and Exchange Commission (the "SEC"). Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statements or other information, whether as a result of new information, future events or otherwise.

###

-2-

---

IR Contacts:	<b>Kevin C. Mannix</b>	United States	(215) 591-8912
	<b>Ran Meir</b>	United States	(215) 591-3033
	<b>Tomer Amitai</b>	Israel	972 (3) 926-7656
PR Contacts:	<b>Iris Beck Codner</b>	Israel	972 (3) 926-7687
	<b>Denise Bradley</b>	United States	(215) 591-8974